Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects

Authors not listed

SK Chemicals Co., Ltd. · 2014

Abstract

All participants received a single dose of their assigned vaccine on Day 0. They were followed up for immunogenicity and safety through Day 21 post-vaccination. Serious adverse events were collected for 6 months post-vaccination.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2014). A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects. <em>SK Chemicals Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT02467842
Vancouver
Anonymous. A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects. SK Chemicals Co., Ltd.. 2014.
BibTeX
@misc{anon2014AMulti, title = {A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects}, author = {Anonymous}, journal = {SK Chemicals Co., Ltd.}, year = {2014}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings